Mechanisms of resistance to imatinib mesylate

被引：0
|
作者：
Roche-Lestienne, Catherine [1 ,2 ]
Preudhomme, Claude [1 ,3 ]
机构：
[1] Inst Rech Canc Lille, Unite Inserm 817, 1 Pl Verdun, F-59045 Lille, France
[2] Hop Jeanne Flandre, CHRU Lille, Lab Genel Med, F-59037 Lille, France
[3] Hop Albert Calmette, CHRU Lille, Lab Hematol A, F-59037 Lille, France
来源：
HEMATOLOGIE | 2006年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：11 / 18
页数：8
相关论文
共 50 条
  • [41] Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells
    Luzzatto, L
    Melo, JV
    BLOOD, 2002, 100 (03) : 1105 - 1105
  • [42] Biomarkers for diagnosis and targeting of resistance and sensitivity to imatinib mesylate in chronic myelogenous leukemia
    Goldknopf, IL
    Sheta, EA
    Talpaz, M
    Cortes, J
    Albitar, M
    Kantarjian, H
    FASEB JOURNAL, 2006, 20 (04): : A499 - A499
  • [43] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Pennisi, M. S.
    Stagno, F.
    Massimino, M.
    Stella, S.
    Di Raimondo, F.
    Messina, A.
    Vigneri, P.
    HAEMATOLOGICA, 2008, 93 : S66 - S66
  • [44] Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
    H G Jørgensen
    E K Allan
    S M Graham
    J L Godden
    L Richmond
    M A Elliott
    J C Mountford
    C J Eaves
    T L Holyoake
    Leukemia, 2005, 19 : 1184 - 1191
  • [45] Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance
    Tseng, PH
    Lin, HP
    Zhu, JX
    Chen, KF
    Hade, EM
    Young, DC
    Byrd, JC
    Grever, M
    Johnson, K
    Druker, BJ
    Chen, CS
    BLOOD, 2005, 105 (10) : 4021 - 4027
  • [46] Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
    Jorgensen, HG
    Allan, EK
    Graham, SM
    Godden, JL
    Richmond, L
    Elliott, MA
    Mountford, JC
    Eaves, CJ
    Holyoake, TL
    LEUKEMIA, 2005, 19 (07) : 1184 - 1191
  • [47] Novel Agents to Override Imatinib Resistance Mechanisms
    Yokota, Asumi
    Kimura, Shinya
    DRUG DEVELOPMENT RESEARCH, 2008, 69 (07) : 398 - 406
  • [48] Resistance to imatinib (Glivec): update on clinical mechanisms
    Weisberg, E
    Griffin, JD
    DRUG RESISTANCE UPDATES, 2003, 6 (05) : 231 - 238
  • [49] Inhibition of mTOR by rapamycin enhances killing of CML cells by imatinib mesylate and overcomes certain forms of imatinib resistance.
    Halbur, L
    Ly, C
    Ong, ST
    BLOOD, 2003, 102 (11) : 72A - 72A
  • [50] Imatinib mesylate - A viewpoint by Ian Judson
    Judson, I
    DRUGS, 2003, 63 (05) : 523 - 523
12345